BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37616559)

  • 21. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells.
    Wang H; Zou J; Zhao B; Johannsen E; Ashworth T; Wong H; Pear WS; Schug J; Blacklow SC; Arnett KL; Bernstein BE; Kieff E; Aster JC
    Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14908-13. PubMed ID: 21737748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers.
    Wang H; Zang C; Taing L; Arnett KL; Wong YJ; Pear WS; Blacklow SC; Liu XS; Aster JC
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):705-10. PubMed ID: 24374627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch dimerization is required for leukemogenesis and T-cell development.
    Liu H; Chi AW; Arnett KL; Chiang MY; Xu L; Shestova O; Wang H; Li YM; Bhandoola A; Aster JC; Blacklow SC; Pear WS
    Genes Dev; 2010 Nov; 24(21):2395-407. PubMed ID: 20935071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
    Sharma VM; Calvo JA; Draheim KM; Cunningham LA; Hermance N; Beverly L; Krishnamoorthy V; Bhasin M; Capobianco AJ; Kelliher MA
    Mol Cell Biol; 2006 Nov; 26(21):8022-31. PubMed ID: 16954387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.
    Mavrakis KJ; Wolfe AL; Oricchio E; Palomero T; de Keersmaecker K; McJunkin K; Zuber J; James T; Khan AA; Leslie CS; Parker JS; Paddison PJ; Tam W; Ferrando A; Wendel HG
    Nat Cell Biol; 2010 Apr; 12(4):372-9. PubMed ID: 20190740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
    Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
    Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
    Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency.
    Blackburn JS; Liu S; Raiser DM; Martinez SA; Feng H; Meeker ND; Gentry J; Neuberg D; Look AT; Ramaswamy S; Bernards A; Trede NS; Langenau DM
    Leukemia; 2012 Sep; 26(9):2069-78. PubMed ID: 22538478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notch protection against apoptosis in T-ALL cells mediated by GIMAP5.
    Chadwick N; Zeef L; Portillo V; Boros J; Hoyle S; van Doesburg JC; Buckle AM
    Blood Cells Mol Dis; 2010 Oct; 45(3):201-9. PubMed ID: 20817506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.
    Herranz D; Ambesi-Impiombato A; Palomero T; Schnell SA; Belver L; Wendorff AA; Xu L; Castillo-Martin M; Llobet-Navás D; Cordon-Cardo C; Clappier E; Soulier J; Ferrando AA
    Nat Med; 2014 Oct; 20(10):1130-7. PubMed ID: 25194570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
    Ren M; Cowell JK
    Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis.
    Gómez-del Arco P; Kashiwagi M; Jackson AF; Naito T; Zhang J; Liu F; Kee B; Vooijs M; Radtke F; Redondo JM; Georgopoulos K
    Immunity; 2010 Nov; 33(5):685-98. PubMed ID: 21093322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.